Share
1,137 Posts.
lightbulb Created with Sketch. 816
clock Created with Sketch.
18/08/22
10:03
Share
Originally posted by needle:
↑
Less likely now, as days go bye - we will get anymore on the presentation from Dr J Yang... in the short term at least. The company has undertaken many dozens of presentations - but this time, it is the radiation CNS boss at Memorial Sloan presenting on paxalisib. I would think this PowerPoint talk - comparing the "qualities" of paxalisib, with 3 other approved drugs - ( and the trial results, of course) - sits way ahead of anything ever from the CEO in the past. The background slide is the thing that really appeals to me. Further to an earlier post - a third drug (in addition to Idelalisib and Alpelisib) - Everolimus is also mentioned towards the bottom of the slide........and also matched up for comparison with paxalisib. Everolimus targets the mTOR 1 and mTORC2 complex solely. All these three drugs are FDA approved - none of them are used for CNS cancers or brain metastases. For a period of time - I have suggested paxalisib for primary cancers also - and here we have Memorial Sloan, over the weekend.... effectively presenting a technical match up with not one or 2 - but 3 other drugs marketed for primary and blood cancers. Needless to say - that is the point from Dr Yang - he believes paxalisib comes out on top. ----------------------- This share price is one crazy and bizarre situation - the brief discussion in this post....maybe could hardly sum up the stupidity better. Cap A$37m - cash $6m
Expand
Very disappointing and frustrating no further presentations or updates from Dr J Yang or Dr P Brastianos. Looking forward to what the Chairman and CEO has to say in Kazia's annual report next week. Regards.